12:00 AM
 | 
Mar 20, 2000
 |  BioCentury  |  Finance

Waiting for the verdict

All eyes will be on Celltech as the London Stock Exchange opens for business on Monday, the first day it will trade as a FTSE 100 company. The LSE was closed when an FDA advisory committee on Friday recommended a limited label for CCH's Mylotarg gemtuzumab zogamicin in acute myeloid leukemia (AML), which was presented to the panel by partner Wyeth-Ayerst. Rumors that the product had been rejected prompted a halt in trading of the company's ADRs on the New York Stock Exchange at $36.375, down $4.125 on the day. CCH closed Friday at 1307.5p, up 72.5p on the day, but down 470p on the week at a market cap of £10.4 billion ($16.4 billion). (see Regulation, A6).

Private rounds

AdProTech raised £5 million ($7.9 million) in a second funding round. The autoimmune and inflammation company will use the funds to move APT070, a membrane-targeted complement inhibitor, into preclinical studies. APT070 has potential applications in rheumatoid arthritis, pretreatment of organs to prevent ischemia, and other complement-mediated pathology. Investors were 3i, Prelude Trust, Alta Berkeley Associates and Alice Ventures.

Fund watch

Amerindo Investment Advisors unveiled a new life sciences fund - the Amerindo Health & Biotechnology Fund - that will invest in both biotechnology and internet health care. The fund will be based on the firm's concentrated investment style of taking large initial positions in a limited number of core stocks. Amerindo President Alberto Vilar will serve as fund manager. . . . speaking of Amerindo, portfolio manager Bill Slattery left the firm to join Jackie Siegel at Deerfield Management, a $1 billion hedge fund, where he will focus on biotech, genomics and ehealth investments. Slattery had been at Amerindo since 1993.

Venture tracks

Mark Clement officially joined Merlin Bioscience...

Read the full 1420 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >